Targeting T regulatory (T_reg) cells in immunotherapy-resistant cancers

Abstract

Primary or secondary (i.e., acquired) resistance is a common occurrence in cancer patients and is often associated with high numbers of T regulatory (T_reg) cells (CD4⁺CD25⁺FOXP3⁺). The approval of ipilimumab and the development of similar pharmacological agents targeting cell surface proteins on T_reg cells demonstrates that such intervention may overcome resistance in cancer patients. Hence, the clinical development and subsequent approval of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) targeting agents can serve as a prototype for similar agents. Such new agents aspire to be highly specific and have a reduced toxicity profile while increasing effector T cell function or effector T/T regulatory (T_eff/T_reg) ratio. While clinical development with large molecules has shown the greatest advancement, small molecule inhibitors that target immunomodulation are increasingly entering early clinical investigation. These new small molecule inhibitors often target specific intracellular signaling pathways [e.g., phosphoinositide-3-kinase delta (PI3K-δ)] that play an important role in regulating the function of T_reg cells. This review will summarize the lessons currently applied to develop novel clinical agents that target T_reg cells.

Keywords

Primary and secondary resistance / T regulatory cells / flow cytometry / mass cytometry / hyperprogression

References

[1] Vaddepally RK,Pandey R,Chandra AB.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.Cancers2020;12:738 PMCID:PMC7140028

[2] Marei HE,Pozzoli G.Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.Cancer Cell Int2023;23:64 PMCID:PMC10088229

[3] Pai SI,Marincola FM.The paradox of cancer immune exclusion: immune oncology next frontier. In: Lee PP, Marincola FM, editors. Tumor microenvironment. Cham: Springer International Publishing; 2020. pp. 173-95. PMCID:PMC7423459

[4] Gajewski TF,Williams J,Sivan A.Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. In: Kalinski P, editor. Tumor immune microenvironment in cancer progression and cancer therapy. Cham: Springer International Publishing; 2017. pp. 19-31. PMCID:PMC6693322

[5] Mellman I,Powles T.The cancer-immunity cycle: indication, genotype, and immunotype.Immunity2023;56:2188-205

[6] Chen DS.Elements of cancer immunity and the cancer-immune set point.Nature2017;541:321-30

[7] Clifton GT,Ascierto PA.Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop.J Immunother Cancer2023;11:e006773 PMCID:PMC10254706

[8] Bagaev A,Nomie K.Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.Cancer Cell2021;39:845-65.e7

[9] Salmon H,Gnjatic S.Host tissue determinants of tumour immunity.Nat Rev Cancer2019;19:215-27 PMCID:PMC7787168

[10] Bu X,Freeman GJ.Learning from PD-1 resistance: new combination strategies.Trends Mol Med2016;22:448-51 PMCID:PMC6833952

[11] Sharma A.Emerging functions of regulatory T cells in tissue homeostasis.Front Immunol2018;9:883 PMCID:PMC5989423

[12] Nishikawa H.Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.J Immunother Cancer2021;9:e002591 PMCID:PMC8327843

[13] Shevach EM.CD4⁺CD25⁺ suppressor T cells: more questions than answers.Nat Rev Immunol2002;2:389-400

[14] Gershon RK.Infectious immunological tolerance.Immunology1971;21:903-14 PMCID:PMC1408252

[15] Gershon RK.Cell interactions in the induction of tolerance: the role of thymic lymphocytes.Immunology1970;18:723-37 PMCID:PMC1455602

[16] Nishizuka Y.Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice.Science1969;166:753-5

[17] Astarita JL,Tan C.Treg specialization and functions beyond immune suppression.Clin Exp Immunol2023;211:176-83 PMCID:PMC10019124

[18] Sakaguchi S,Asano M,Toda M.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol1995;155:1151-64

[19] O’Garra A.Role of cytokines in determining T-lymphocyte function.Curr Opin Immunol1994;6:458-66

[20] Peng G,Wu W,Chen Y.Circulating CD4⁺ CD25⁺ regulatory T cells correlate with chronic hepatitis B infection.Immunology2008;123:57-65 PMCID:PMC2433275

[21] Apostolou I.In vivo instruction of suppressor commitment in naive T cells.J Exp Med2004;199:1401-8 PMCID:PMC2211808

[22] Safinia N,Vaikunthanathan T,Lombardi G.Regulatory T cells: serious contenders in the promise for immunological tolerance in transplantation.Front Immunol2015;6:438 PMCID:PMC4553385

[23] Jonuleit H.The regulatory T cell family: distinct subsets and their interrelations.J Immunol2003;171:6323-7

[24] Abbas AK,Bluestone JA.Regulatory T cells: recommendations to simplify the nomenclature.Nat Immunol2013;14:307-8

[25] Hsieh CS,Lio CWJ.Selection of regulatory T cells in the thymus.Nat Rev Immunol2012;12:157-67

[26] Josefowicz SZ.Control of regulatory T cell lineage commitment and maintenance.Immunity2009;30:616-25 PMCID:PMC4410181

[27] Bilate AM.Induced CD4⁺Foxp3⁺ regulatory T cells in immune tolerance.Annu Rev Immunol2012;30:733-58

[28] Yano H,Workman CJ.Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.Immunology2019;157:232-47 PMCID:PMC6587321

[29] Georgiev P,Chatila TA.Regulatory T cells: the many faces of Foxp3.J Clin Immunol2019;39:623-40 PMCID:PMC6754763

[30] Weinberg SE.Toward a paradigm to distinguish distinct functions of FOXP3⁺ regulatory T cells.Immunohorizons2021;5:944-52 PMCID:PMC8691855

[31] Huang L,Liu S.Targeting regulatory T cells for immunotherapy in melanoma.Mol Biomed2021;2:11 PMCID:PMC8591697

[32] Saison J,Venet F.CD4⁺CD25⁺CD127^- assessment as a surrogate phenotype for FOXP3⁺ regulatory T cells in HIV-1 infected viremic and aviremic subjects.Cytometry B Clin Cytom2013;84B:50-4

[33] Klein S,Krammer PH.CD127^low/- and FoxP3⁺ expression levels characterize different regulatory T-cell populations in human peripheral blood.J Invest Dermatol2010;130:492-9

[34] Ohue Y.Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?.Cancer Sci2019;110:2080-9 PMCID:PMC6609813

[35] Togashi Y,Nishikawa H.Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.Nat Rev Clin Oncol2019;16:356-71

[36] Huppert LA,Kim L.Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy.Cell Mol Immunol2022;19:33-45 PMCID:PMC8752797

[37] Eyoh E,Killick J,Mutapi F.The anthelmintic drug praziquantel promotes human Tr1 differentiation.Immunol Cell Biol2019;97:512-8

[38] Zhao H,Kang Y.Tregs: where we are and what comes next?.Front Immunol2017;8:1578 PMCID:PMC5705554

[39] Akimova T,Wang L,Hancock WW.Helios expression is a marker of T cell activation and proliferation.PLoS One2011;6:e24226 PMCID:PMC3168881

[40] Aksoylar HI.PD-1⁺ T_reg cells: a foe in cancer immunotherapy?.Nat Immunol2020;21:1311-2 PMCID:PMC10754338

[41] Dykema AG,Cheung LS.Lung tumor-infiltrating T_reg have divergent transcriptional profiles and function linked to checkpoint blockade response.Sci Immunol2023;8:eadg1487 PMCID:PMC10629528

[42] Di Giorgio E,Xiong Y.MEF2D sustains activation of effector Foxp3⁺ Tregs during transplant survival and anticancer immunity.J Clin Invest2020;130:6242-60 PMCID:PMC7685736

[43] Dolsten GA.Genomic analysis of Foxp3 function in regulatory T cells.J Immunol2023;210:880-7

[44] Trujillo-Ochoa JL,Afzali B.The role of transcription factors in shaping regulatory T cell identity.Nat Rev Immunol2023;23:842-56

[45] Obradovic A,Turunen M.Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators.Cancer Cell2023;41:933-49.e11

[46] Rapp M,Kunz WG.CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.J Exp Med2019;216:1170-81 PMCID:PMC6504218

[47] Iellem A,Lang R.Unique chemotactic response profile and specific expression of chemokine receptors Ccr4 and Ccr8 by Cd4⁺Cd25⁺ regulatory T cells.J Exp Med2001;194:847-53 PMCID:PMC2195967

[48] Sugiyama D,Maeda Y.Anti-CCR4 mAb selectively depletes effector-type FoxP3⁺CD4⁺ regulatory T cells, evoking antitumor immune responses in humans.Proc Natl Acad Sci U S A2013;110:17945-50 PMCID:PMC3816454

[49] Sarkar T,Chakraborty D.FOXP3/HAT1 axis controls Treg infiltration in the tumor microenvironment by inducing CCR4 expression in breast cancer.Front Immunol2022;13:740588 PMCID:PMC8863663

[50] Medof ME,Shevach EM.Disabled C3ar1/C5ar1 signaling in Foxp3⁺ T regulatory cells leads to TSDR demethylation and long-term stability.J Immunol2023;211:1359-66

[51] Bayati F,Valadi M,Foma AM.The therapeutic potential of regulatory T cells: challenges and opportunities.Front Immunol2020;11:585819 PMCID:PMC7844143

[52] Dennis KL,Gounari F.Current status of interleukin-10 and regulatory T-cells in cancer.Curr Opin Oncol2013;25:637-45 PMCID:PMC4322764

[53] Hsu P,Hu M.IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1.J Immunol2015;195:3665-74

[54] Konkel JE,Zanvit P.Transforming growth factor-β signaling in regulatory T cells controls T helper-17 cells and tissue-specific immune responses.Immunity2017;46:660-74

[55] Wan YY.TGF-β and regulatory T cell in immunity and autoimmunity.J Clin Immunol2008;28:647-59 PMCID:PMC2837280

[56] Pyzik M.TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4⁺ T cell subsets.J Leukoc Biol2007;82:335-46

[57] Chen W.TGF-β regulation of T cells.Annu Rev Immunol2023;41:483-512

[58] Jain N,Chambers C.Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.Proc Natl Acad Sci U S A2010;107:1524-8 PMCID:PMC2824392

[59] Ledford H,Warren M.Cancer immunologists scoop medicine Nobel prize.Nature2018;562:20-1

[60] Da M,Enk A,Mahnke K.The multifaceted actions of CD73 during development and suppressive actions of regulatory T cells.Front Immunol2022;13:914799 PMCID:PMC9197450

[61] Chen S,Zhang M.CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.Nat Commun2019;10:150 PMCID:PMC6329764

[62] Nelson BH.IL-2, regulatory T cells, and tolerance.J Immunol2004;172:3983-8

[63] Gasteiger G.Foxp3⁺ regulatory T-cells and IL-2: the moirai of T-cell fates?.Front Immunol2012;3:179 PMCID:PMC3395027

[64] Xydia M,Ruggiero E.Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients.Nat Commun2021;12:1119 PMCID:PMC7893042

[65] Fan MY,Tanimine N.Differential roles of IL-2 signaling in developing versus mature Tregs.Cell Rep2018;25:1204-13.e4 PMCID:PMC6289175

[66] Shapiro MR,Brown ME.Insulin-like growth factor-1 synergizes with IL-2 to induce homeostatic proliferation of regulatory T cells.J Immunol2023;211:1108-22 PMCID:PMC10511790

[67] O’Rourke DM,Desai A.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Sci Transl Med2017;9:eaaa0984 PMCID:PMC5762203

[68] Wang L,Blanchard M.Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13Rα2-targeting CAR T cells: an interim analysis.Res Sq2023;In Press:

[69] Wang H,Tsui YC.CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.Nat Immunol2020;21:298-308 PMCID:PMC7043937

[70] Stroukov W,Albany CJ,Lombardi G.OMIP-090: a 20-parameter flow cytometry panel for rapid analysis of cell diversity and homing capacity in human conventional and regulatory T cells.Cytometry A2023;103:362-7

[71] Santegoets SJAM,Battaglia A.Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.Cancer Immunol Immunother2015;64:1271-86 PMCID:PMC4554737

[72] Mason GM,Melchiotti R.Phenotypic complexity of the human regulatory T cell compartment revealed by mass cytometry.J Immunol2015;195:2030-7

[73] Barcenilla H,Sjögren F,Casas R.Regulatory T-cell phenotyping using CyTOF. In: Ono M, editor. Regulatory T-cells. New York: Springer US; 2023. pp. 231-42.

[74] Jaimes MC,Kraker G,Maecker H.Full spectrum flow cytometry and mass cytometry: a 32-marker panel comparison.Cytometry A2022;101:942-59 PMCID:PMC9790709

[75] Di Giacomo AM,Amato G et al. 139P - First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3K-d) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma. 2021. Available from: https://www.ionctura.com/admin/resources/139pdi-giacomoioa244esmo-io-2021final.pdf. [Last accessed on 11 Jan 2024]

[76] Singh U,Dimaano N.Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte biomarkers.Biotech Histochem2018;93:411-23

[77] Amgad M, Stovgaard ES, Balslev E, et al; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer 2020;6:16. PMCID:PMC7217824

[78] Halse H,Petrone P.Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.Sci Rep2018;8:11158 PMCID:PMC6057961

[79] Harms PW,Moutafi M.Multiplex immunohistochemistry and immunofluorescence: a practical update for pathologists.Mod Pathol2023;36:100197

[80] Hsieh WC,Wang YF.Spatial multi-omics analyses of the tumor immune microenvironment.J Biomed Sci2022;29:96 PMCID:PMC9661775

[81] Andreatta M,Müller S,Coukos G.Interpretation of T cell states from single-cell transcriptomics data using reference atlases.Nat Commun2021;12:2965 PMCID:PMC8137700

[82] Höllbacher B,Motley S,Gratz IK.Transcriptomic profiling of human effector and regulatory T cell subsets identifies predictive population signatures.Immunohorizons2020;4:585-96 PMCID:PMC8085975

[83] Hui Z,Zheng Y.Single-cell sequencing reveals the transcriptome and TCR characteristics of pTregs and in vitro expanded iTregs.Front Immunol2021;12:619932 PMCID:PMC8044526

[84] Cuadrado E,de Kivit S.Proteomic analyses of human regulatory T cells reveal adaptations in signaling pathways that protect cellular identity.Immunity2018;48:1046-59.e6

[85] Mensink M,Cuadrado E,de Kivit S.Proteomics reveals unique identities of human TGF-β-induced and thymus-derived CD4⁺ regulatory T cells.Sci Rep2022;12:20268 PMCID:PMC9700829

[86] Duguet F,Marcellin M.Proteomic analysis of regulatory T cells reveals the importance of themis1 in the control of their suppressive function.Mol Cell Proteomics2017;16:1416-32 PMCID:PMC5546195

[87] Matheu MP,Greenberg ML.Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming.Nat Commun2015;6:6219 PMCID:PMC4347855

[88] Kist de Ruijter L,Hooiveld-Noeken JS.Whole-body CD8⁺ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.Nat Med2022;28:2601-10 PMCID:PMC9800278

[89] Abdeladhim M,Rieder SA.In or out of control: modulating regulatory T cell homeostasis and function with immune checkpoint pathways.Front Immunol2022;13:1033705 PMCID:PMC9799097

[90] Ballman KV.Biomarker: predictive or prognostic?.J Clin Oncol2015;33:3968-71

[91] Shang B,Jiang SJ.Prognostic value of tumor-infiltrating FoxP3⁺ regulatory T cells in cancers: a systematic review and meta-analysis.Sci Rep2015;5:15179 PMCID:PMC4604472

[92] Li L,Yin Z,Yan D.Increased frequency of regulatory T cells in the peripheral blood of patients with endometrioid adenocarcinoma.Oncol Lett2019;18:1424-30 PMCID:PMC6607055

[93] Kolben T,Perleberg C.Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells.Cell Oncol2022;45:1171-85 PMCID:PMC9747805

[94] Qiu J,Zeng X.CCL5 mediates breast cancer metastasis and prognosis through CCR5/Treg cells.Front Oncol2022;12:972383 PMCID:PMC9399502

[95] Petersen RP,Sperlazza J.Tumor infiltrating Foxp3⁺ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.Cancer2006;107:2866-72

[96] Karagöz B,Gümüs M.CD8⁺CD28^- cells and CD4⁺CD25⁺ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.Med Oncol2010;27:29-33

[97] Erfani N,Ghayumi MA.Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC).Lung Cancer2012;77:306-11

[98] Hu X,Zhao S,Jiang Y.Elevated circulating CD4⁺CD25^-Foxp3⁺ regulatory T cells in patients with nonsmall cell lung cancer.Cancer Biother Radiopharm2019;34:325-33

[99] Li S,Qu X,Liang J.Detection and significance of TregFoxP3⁺ and Th17 cells in peripheral blood of non-small cell lung cancer patients.Arch Med Sci2014;10:232-9

[100] Chen C,Zhang Y.Changes of CD4⁺CD25⁺FOXP3⁺ and CD8⁺CD28^- regulatory T cells in non-small cell lung cancer patients undergoing surgery.Int Immunopharmacol2014;18:255-61

[101] Kotsakis A,Katsarou A.Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.Sci Rep2016;6:39247 PMCID:PMC5157012

[102] Luo JW,Wu FY.Differences in immunological landscape between EGFR-mutated and wild-type lung adenocarcinoma.Dis Markers2021;2021:3776854 PMCID:PMC8416409

[103] Sugiyama E,Takeuchi Y.Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer.Sci Immunol2020;5:eaav3937

[104] Bjoern J,Zeeberg Iversen T,Fode K.Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.Oncoimmunology2016;5:e1100788 PMCID:PMC4839337

[105] Gambichler T,Höxtermann S,Stockfleth E.Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade.Br J Dermatol2020;182:1214-20

[106] Pircher A,Amann A.Neoadjuvant chemo-immunotherapy modifies CD4⁺CD25⁺ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.Lung Cancer2014;85:81-7

[107] Koh J,Lee KY.Regulatory (FoxP3⁺) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer.Sci Rep2020;10:18994 PMCID:PMC7642363

[108] Kumagai S,Kamada T.The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.Nat Immunol2020;21:1346-58

[109] Santagata S,Rea G.Abstract 6675: basal NK activity and early Tregs inhibition predicts nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.Cancer Res2020;80:6675

[110] Di Giacomo AM,Amato G.First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.J Clin Oncol2022;40:3107

[111] Kamphorst AO,Yang S.Proliferation of PD-1⁺ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.Proc Natl Acad Sci U S A2017;114:4993-8 PMCID:PMC5441721

[112] De Simone M,Rossetti G.Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells.Immunity2016;45:1135-47 PMCID:PMC5119953

[113] Plitas G,Wu K.Regulatory T cells exhibit distinct features in human breast cancer.Immunity2016;45:1122-34 PMCID:PMC5134901

[114] Barsheshet Y,Levy E.CCR8⁺FOXp3⁺ T_reg cells as master drivers of immune regulation.Proc Natl Acad Sci U S A2017;114:6086-91 PMCID:PMC5468670

[115] Zdanov S,Abu Eid R.Mutant KRAS conversion of conventional T cells into regulatory T cells.Cancer Immunol Res2016;4:354-65 PMCID:PMC4884020

[116] Kalvala A,Yang L.Phenotypic switching of naïve T cells to immune-suppressive Treg-like cells by mutant KRAS.J Clin Med2019;8:1726

[117] Kumagai S,Itahashi K.Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.Cancer Cell2022;40:201-18.e9

[118] Wang J.The four types of Tregs in malignant lymphomas.J Hematol Oncol2011;4:50 PMCID:PMC3253040

[119] Peng F,Mu S,Ai L.Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis.J Cancer Res Clin Oncol2020;146:3123-35

[120] Nixon AB,Jacobs I,Wang IM.Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?.J Immunother Cancer2019;7:325 PMCID:PMC6880594

[121] Ding P,Tong F,Huang Y.Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.Cancer Drug Resist2022;5:147-64 PMCID:PMC8992596

[122] Zang H,Zheng H.Hyperprogression after immune-checkpoint inhibitor treatment: characteristics and hypotheses.Front Oncol2020;10:515 PMCID:PMC7201048

[123] Kamada T,Tay C.PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.Proc Natl Acad Sci U S A2019;116:9999-10008 PMCID:PMC6525547

[124] Woods DM,Laino AS.Decreased suppression and increased phosphorylated STAT3 in regulatory T cells are associated with benefit from adjuvant PD-1 blockade in resected metastatic melanoma.Clin Cancer Res2018;24:6236-47 PMCID:PMC6295261

[125] Gadi D,Tyekucheva S.A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.Leukemia2022;36:723-32 PMCID:PMC8891037

[126] Weidner AS,Geyer JT.Idelalisib-associated colitis: histologic findings in 14 patients.Am J Surg Pathol2015;39:1661-7

[127] Manna A,Aulakh S.Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8⁺ T-cell responses.Blood Adv2020;4:2143-57 PMCID:PMC7252547

[128] Jitschin R,Büttner M.CLL-cells induce IDO^hi CD14⁺HLA-DR^lo myeloid-derived suppressor cells that inhibit T-cell responses and promote T_Regs.Blood2014;124:750-60

[129] Mékinian A,Belkacem KA.Immuno-regulatory malignant B cells contribute to chronic lymphocytic leukemia progression.Cancer Gene Ther2023;30:1018-28 PMCID:PMC10353928

[130] Massa M,Campanelli R,Barosi G.Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.Leukemia2014;28:449-51

[131] Keohane C,Seidl T.JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.Br J Haematol2015;171:60-73

[132] Arce Vargas F,Litchfield K.Fc effector function contributes to the activity of human anti-CTLA-4 antibodies.Cancer Cell2018;33:649-63.e4

[133] Galvez-Cancino F,Costoya C.Fcγ receptors and immunomodulatory antibodies in cancer.Nat Rev Cancer2024;24:51-71

[134] Chen CM,Chen JF.Characterization of the in vitro metabolites of idelalisib in liver microsomes and interspecies comparison.J Pharm Biomed Anal2019;162:249-56

[135] Shin N,Koblish H.Parsaclisib is a next-generation phosphoinositide 3-kinase δ inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy.J Pharmacol Exp Ther2020;374:211-22

[136] Vangapandu HV,Gandhi V.Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.Expert Opin Investig Drugs2017;26:625-32 PMCID:PMC5584596

[137] Gadkar K,Hurez V.Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors.CPT Pharmacometrics Syst Pharmacol2022;11:616-27 PMCID:PMC9124351

[138] Sharma A,Blando J.Anti-CTLA-4 immunotherapy does not deplete FOXP3⁺ regulatory T cells (Tregs) in human cancers.Clin Cancer Res2019;25:1233-8 PMCID:PMC6348141

[139] Retseck J,Lin Y.Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.J Transl Med2018;16:184 PMCID:PMC6033230

[140] Patel TH,Fan J.FDA approval summary: tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. Clin Cancer Res 2023;30:269-73.

[141] Lowther DE,Lucca LE.PD-1 marks dysfunctional regulatory T cells in malignant gliomas.JCI Insight2016;1:e85935 PMCID:PMC4864991

[142] Hong DS,Chiu VK.Mogamulizumab in combination with nivolumab in a phase I/II study of patients with locally advanced or metastatic solid tumors.Clin Cancer Res2022;28:479-88 PMCID:PMC9401557

[143] Kidani Y,Yasumizu Y.CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.Proc Natl Acad Sci U S A2022;119:e2114282119 PMCID:PMC8851483

[144] Weaver JD,Buggé JA.Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.Oncoimmunology2022;11:2141007 PMCID:PMC9639568

[145] Solomon I,Goubier A.CD25-T_reg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.Nat Cancer2020;1:1153-66 PMCID:PMC7116816

[146] Wyant T,Ahern E.Abstract C033: preliminary pharmacodynamic evaluation of AU-007 in phase 1 dose escalation trial in patients with advanced solid tumors.Mol Cancer Ther2023;22:C033

[147] Cole CB,Fantini M.Correction: first-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.J Exp Clin Cancer Res2023;42:102 PMCID:PMC10131449

[148] Le DT.Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.Cancer Res2012;72:3439-44 PMCID:PMC3399042

[149] Ghiringhelli F,Puig PE.Metronomic cyclophosphamide regimen selectively depletes CD4⁺CD25⁺ regulatory T cells and restores T and NK effector functions in end stage cancer patients.Cancer Immunol Immunother2007;56:641-8

[150] Scurr M,Bloom A.Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer.Clin Cancer Res2017;23:6771-80 PMCID:PMC5769815

[151] Roselli M,di Bari MG.Effects of conventional therapeutic interventions on the number and function of regulatory T cells.Oncoimmunology2013;2:e27025 PMCID:PMC3862634

[152] Revenko A,Sinclair C.Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.J Immunother Cancer2022;10:e003892 PMCID:PMC8987763

[153] Eschweiler S,Li Y.Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.Nature2022;605:741-6 PMCID:PMC9132770

[154] Tarantelli C,Zinzani PL.PI3Kδ inhibitors as immunomodulatory agents for the treatment of lymphoma patients.Cancers2021;13:5535 PMCID:PMC8582887

[155] Scirocchi F,Botticelli A.Immune effects of CDK4/6 inhibitors in patients with HR⁺/HER2^- metastatic breast cancer: relief from immunosuppression is associated with clinical response.EBioMedicine2022;79:104010 PMCID:PMC9061627

[156] Kohlhapp FJ,Mathew R.Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade.Cancer Discov2021;11:68-79

[157] Anandappa AJ,Ott PA.Directing traffic: how to effectively drive T cells into tumors.Cancer Discov2020;10:185-97 PMCID:PMC7007384

[158] Wei T,Li Q.Role of heterogeneous regulatory T cells in the tumor microenvironment.Pharmacol Res2020;153:104659

[159] Principe DR,Mohindra NA.Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung cancer.Front Oncol2021;11:684098 PMCID:PMC8204014

[160] Korman AJ,Lonberg N.The foundations of immune checkpoint blockade and the ipilimumab approval decennial.Nat Rev Drug Discov2022;21:509-28

[161] Jameson-Lee M.Ipilimumab combination dosing: less is more.Clin Cancer Res2021;27:5153-5 PMCID:PMC8807780

[162] Di Giacomo AM,Eggermont AM.The future of targeting cytotoxic T-lymphocyte-associated protein-4: is there a role?.Eur J Cancer2023;198:113501

[163] Maio M,Necchi A.Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: the future is now!.Eur J Cancer2021;152:155-64

[164] Peña-Asensio J,Torralba M,Sanz-de-Villalobos E.Anti-PD-1/PD-L1 based combination immunotherapy to boost antigen-specific CD8⁺ T cell response in hepatocellular carcinoma.Cancers2021;13:1922 PMCID:PMC8073815

[165] Gianchecchi E.Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression.Front Immunol2018;9:2374 PMCID:PMC6199356

[166] Moore DC,Shibu PA,Park SI.Mogamulizumab: an anti-CC chemokine receptor 4 antibody for T-cell lymphomas.Ann Pharmacother2020;54:371-9

[167] Orcutt-Jahns BT,Snyder EM,Meyer AS.Multivalent, asymmetric IL-2-Fc fusions show enhanced selectivity for regulatory T cells.Sci Signal2023;16:eadg0699

[168] Fattori S,Houacine J.CD25^high effector regulatory T cells hamper responses to PD-1 blockade in triple-negative breast cancer.Cancer Res2023;83:3026-44 PMCID:PMC10502453

[169] Simonelli M,Eskens F.Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.ESMO Open2022;7:100562 PMCID:PMC9588873

[170] Tsang K,Cole C,Arlen P.840 A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression. J Immunother Cancer 2021;9:A881.

[171] García-Díaz N,Taskén K.Small molecule inhibitors targeting regulatory T cells for cancer treatment.Eur J Immunol2023;e2350448

[172] Li JY,Wang LP.Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer.J Immunol Res2014;2014:286170 PMCID:PMC4020463

[173] Deng B,Chen J.Gallic acid induces T-helper-1-like T_reg cells and strengthens immune checkpoint blockade efficacy.J Immunother Cancer2022;10:e004037 PMCID:PMC9274539

[174] Marshall LA,Jorapur A.Tumors establish resistance to immunotherapy by regulating T_reg recruitment via CCR4.J Immunother Cancer2020;8:e000764 PMCID:PMC7692993

[175] Ketcham JM,Talay O.CCR4 antagonists inhibit T_reg trafficking into the tumor microenvironment.ACS Med Chem Lett2018;9:953-5 PMCID:PMC6187395

[176] Yoshie O.CCR4 as a therapeutic target for cancer immunotherapy.Cancers2021;13:5542 PMCID:PMC8583476

[177] Lim EL.Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.Immunology2019;157:210-8 PMCID:PMC6587315

[178] Ahmad S,Shrimali R.Differential PI3Kδ signaling in CD4⁺ T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy.Cancer Res2017;77:1892-904

[179] Kirkwood JM,Cho D.Abstract CT176: effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: biomarker results from a phase Ib study in patients with advanced solid tumors.Cancer Res2018;78:CT176

[180] Borazanci E,Nemunaitis J,Huang J.A phase Ib study of single-agent idelalisib followed by idelalisib in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.Oncologist2020;25:e1604-13 PMCID:PMC7648342

[181] Haselmayer P,Muzerelle M.Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies.Front Immunol2014;5:233 PMCID:PMC4033217

[182] Johnson Z,Civanelli E.IOA-244 is a non-ATP-competitive, highly selective, tolerable PI3K delta inhibitor that targets solid tumors and breaks immune tolerance.Cancer Res Commun2023;3:576-91 PMCID:PMC10103717

[183] Di Giacomo AM,Amato G.First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).J Clin Oncol2023;41:3110

[184] Schreiber SL.The rise of molecular glues.Cell2021;184:3-9

[185] Bonazzi S,Beckwith REJ.Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.Cell Chem Biol2023;30:235-47.e12

[186] Munn DH,Johnson TS.Treg destabilization and reprogramming: implications for cancer immunotherapy.Cancer Res2018;78:5191-9 PMCID:PMC6139039

[187] Dixon ML,Leavenworth JW.Lineage reprogramming of effector regulatory T cells in cancer.Front Immunol2021;12:717421 PMCID:PMC8355732

[188] Moreno Ayala MA, Li Z, DuPage M. Treg programming and therapeutic reprogramming in cancer.Immunology2019;157:198-209 PMCID:PMC6587317

[189] Keller P,Gao Y.Abstract P106: reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy.Mol Cancer Ther2021;20:P106

[190] Naing A,Klempner SJ.1033P First-in-human study of MALT1 inhibitor MPT-0118: results from monotherapy dose escalation in advanced or metastatic refractory solid tumors.Ann Oncol2023;34:S627-8

[191] Perez SA,Skarlos DV.CD4⁺CD25⁺ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.Clin Cancer Res2007;13:2714-21

[192] Gutierrez L,Zhang T,Alachkar H.Midostaurin reduces regulatory T cells markers in acute myeloid leukemia.Sci Rep2018;8:17544 PMCID:PMC6277419

[193] Wilson KR,Mintern JD.Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy.Immunol Cell Biol2021;99:962-71

[194] Redin E,Lozano T.SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.J Immunother Cancer2021;9:e001496 PMCID:PMC7931761

[195] Pantziarka P,Bouche G.A database of drug repurposing clinical trials in oncology.Front Pharmacol2021;12:790952 PMCID:PMC8635986

[196] Stransky N,Schwab M.Can any drug be repurposed for cancer treatment? A systematic assessment of the scientific literature.Cancers2021;13:6236 PMCID:PMC8699650